Outlook Therapeutics (OTLK) Preferred Dividend Payments (2015 - 2019)
Outlook Therapeutics (OTLK) posted quarterly Preferred Dividend Payments of $166133.0 for Q4 2019, up 10.38% year-over-year from $150508.0 in Q4 2018, and up 2.5% quarter-over-quarter from $162081.0 in Q3 2019.
Outlook Therapeutics (OTLK) Preferred Dividend Payments (2015 - 2019) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Preferred Dividend Payments for 5 consecutive years, with $166133.0 the latest figure, recorded in Q4 2019.
- In Q4 2019, Preferred Dividend Payments rose 10.38% year-over-year to $166133.0; the TTM figure through Sep 2020 stood at $166133.0 (down 73.42% YoY), while the FY2020 annual figure was $166133.0, down 73.42% from the prior year.
- Preferred Dividend Payments improved to $166133.0 in Q4 2019 per OTLK's latest filing, from $162081.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $1.1 million in Q3 2015 and bottomed at $67633.0 in Q1 2015.
- Historically, Preferred Dividend Payments has averaged $495109.3 across 5 years, with a median of $450801.0 in 2017.
- Annual changes were most pronounced in 2016 — Preferred Dividend Payments jumped 1423.54% — and 2019, when it tumbled 75.77%.
- Outlook Therapeutics' Preferred Dividend Payments stood at $939539.0 in 2015, then plunged by 47.51% to $493207.0 in 2016, then retreated by 8.6% to $450801.0 in 2017, then tumbled by 66.61% to $150508.0 in 2018, then grew by 10.38% to $166133.0 in 2019.
- Business Quant data shows OTLK's Preferred Dividend Payments at $166133.0 in Q4 2019, $162081.0 in Q3 2019, and $158128.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 166,133.00 |
| Sep 30, 2019 | 162,081.00 |
| Jun 30, 2019 | 158,128.00 |
| Mar 31, 2019 | 154,271.00 |
| Dec 31, 2018 | 150,508.00 |
| Sep 30, 2018 | 163,822.00 |
| Jun 30, 2018 | 652,612.00 |
| Mar 31, 2018 | 636,695.00 |
| Dec 31, 2017 | 450,801.00 |
| Jun 30, 2016 | 493,207.00 |
| Mar 31, 2016 | 1.03 Mn |
| Dec 31, 2015 | 939,539.00 |
| Sep 30, 2015 | 1.11 Mn |
| Jun 30, 2015 | 1.09 Mn |
| Mar 31, 2015 | 67,633.00 |